Monoamine oxidase enzyme has been developed as a valid target for the treatment of depression. The development of selective and reversible type of monoamine oxidase-A inhibitors still remains a challenge to medicinal chemists pursuing the research towards the search of innovative chemotypes for the management of depressive states. The present chapter focuses on the history of MAO-A inhibitors, structure and biochemistry of MAO-A. It also covers challenges involved in the drug development of MAO-A inhibitors.
About this chapter
Cite this chapter as:Bijo Mathew, Jerad Suresh ;
Monoamine Oxidase-A: A Valid Target for the Management of Depression, Frontiers in Drug Discovery The Search for Antidepressants - An Integrative View of Drug Discovery (2017) 2: 126. https://doi.org/10.2174/9781681084732117020008
Bentham Science Publisher